Skip to main content

Table 1 Characteristics of patients

From: The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients

Number of patients

98

Age (median, range)

58 (19–89)

Sex

 M

57

 F

41

Onset

 Primary

78 (80%)

 Post-MDS/MPN

10 (10%)

 Post-therapy

10 (10%)

Blasts % (median, range)

70 (20-95)

WBC, (median, range) x 109/L

7.9 (0.8–35)

Hb, (median, range) x g/dL

9.6 (4–15.5)

PLT, (median, range) x 109/L

50.5 (1.7–656)

Karyotype

 Normal

40 (41%)

 Abnormal

43 (44%)

 Complex

15 (15%)

WHO classification

 With recurrent abnormalities

44 (44%)

 MDS-related

10 (10%)

 Post-therapy

10 (10%)

 Provisional entities

12 (12%)

 NOS

19 (19%)

 Myeloid sarcoma

3 (3%)

ELN risk

 Favorable

25 (25.5%)

 Intermediate

55 (56.1%)

 Adverse

18 (18.4%)

Treatment

 3 + 7

55 (56.1%)

 Demethylating agents

13 (13.3%)

 LAM 1310

17 (17.3%)

 Supportive therapies

13 (13.3%)

 AlloBMT

22 (22%)